01Approach to the Critical Patient/attcp42

Immediate priorities

›Airway and hemodynamic threats

›Altered mental status suggesting sepsis or intracranial extension

›GCS < 13 — immediate CT head and escalate to resuscitation bay

›Declining GCS or new focal deficits trigger emergent neurosurgery consult

›Sepsis physiology

›SBP < 90 mmHg or MAP < 65 mmHg

›Lactate >= 2 mmol/l

›Temperature > 38.5°C with tachycardia

›Vision-threatening orbital compartment syndrome

›Rapidly progressive proptosis with IOP > 40 mmHg

›New RAPD or acute vision loss — immediate ophthalmology consult

›Initiate IV broad-spectrum antibiotics within 1 hour of suspicion

›Do not delay for imaging when sepsis criteria met

›Blood cultures x 2 before first antibiotic dose

Key stabilization steps

›Vascular access and resuscitation

›Two large-bore IV lines

›IV fluid resuscitation for sepsis: 30 mL/kg crystalloid bolus

›Target MAP >= 65 mmHg

›Anticoagulation initiation after imaging confirms CST

›LMWH preferred over UFH in stable patients

›Do not delay anticoagulation for hemorrhagic venous infarction on imaging

›Continuous cardiac monitoring

›Tachycardia expected — evaluate for septic pulmonary emboli if new arrhythmia

›Oxygen saturation monitoring — SpO2 target >= 94%

Consultation triggers

›Mandatory specialist activation

02History/hx61

Chief complaint and symptom characterization

›Classic presenting symptoms

›Headache — present in >90% of cases

›Progressive over days, often frontal or periorbital

›May be described as the worst headache of life

›Periorbital pain and swelling

›Unilateral onset progressing to bilateral in characteristic cases

›Diplopia — from cranial nerve VI palsy (lateral rectus most commonly affected)

›Vision changes or loss — suggests optic nerve compromise

›Fever — nearly universal in septic CST

›Nausea and vomiting

›Altered mental status or confusion

Preceding infection and timeline

›Source infection history

›Sinusitis — sphenoid and ethmoid most commonly implicated

›Nasal congestion, facial pain/pressure, purulent nasal discharge

›Prior ENT treatments or antibiotic courses

›Facial infections — furuncles, dental abscess, orbital/periorbital cellulitis

›Skin boil or furuncle in the "danger triangle" (nose, upper lip, nasolabial fold)

›Recent dental procedures or tooth extraction

›Ear infection — otitis media, mastoiditis

›Sore throat or pharyngeal infection

›Timing pattern

›Symptoms of primary infection precede CST by 5–10 days

›Mean time from presentation to diagnosis approximately 2.8 days

›Greater than 64% of cases diagnosed >7 days after symptom onset

›Unilateral symptoms progressing to bilateral — highly characteristic time course

›Bilateral spread via intercavernous sinuses over hours to days

03Physical Exam/exam53

Vital signs

›Hemodynamic assessment

›Fever — present in majority of septic CST; temperature > 38.5°C

›High fever with rigors suggests bacteremia

›Tachycardia — expected with sepsis; rate > 100/min

›Hypotension — SBP < 90 mmHg indicates septic shock

›Immediate resuscitation and ICU escalation

›SpO2 — reduced if septic pulmonary emboli present

Ophthalmologic examination

›Orbital and ocular findings

›Proptosis — often unilateral initially, progressing to bilateral

›Measure with Hertel exophthalmometer if available

›Periorbital edema and erythema

›Chemosis — conjunctival edema and injection

›Ptosis

›Ophthalmoplegia — assess all cardinal directions of gaze

›CN VI palsy most common — loss of lateral gaze (abduction)

›CN III palsy — ptosis, mydriasis, downward-outward eye deviation

›CN IV palsy — vertical diplopia, worse on downgaze

›Intraocular pressure measurement

›IOP > 21 mmHg in approximately 54% of cases

›IOP > 40 mmHg suggests orbital compartment syndrome

›Relative afferent pupillary defect (RAPD)

›Swinging flashlight test — critical prognostic finding

›Presence associated with significantly worse visual outcomes and higher mortality

›Fundoscopy

›Papilledema — elevated ICP

›Dilated tortuous retinal veins

04Differential Diagnosis/ddx48

Orbital and periorbital conditions

›Orbital cellulitis — most important mimic

›ICD-10: H05.019

›Distinguishing feature: unilateral, responds to antibiotics, no contralateral spread

›CST suspected when bilateral, rapidly progressive, or antibiotic-unresponsive

›Preseptal (periorbital) cellulitis

›ICD-10: H05.011

›Lacks proptosis, ophthalmoplegia, and systemic toxicity

›Anterior to orbital septum

›Orbital apex syndrome

›Similar cranial nerve III, IV, V, VI involvement

›Typically afebrile, no systemic toxicity

›Usually no proptosis or chemosis

Vascular and structural mimics

›Carotid-cavernous fistula

›ICD-10: I67.1

›Distinguishing: pulsatile proptosis, orbital bruit on auscultation

›Arterialized (red) conjunctival vessels

›No fever or systemic infection

›Pituitary apoplexy

›ICD-10: E23.6

›Sudden severe headache, visual field defects, ophthalmoplegia

›Bitemporal hemianopia and signs of hormonal insufficiency

›Tolosa-Hunt syndrome

›ICD-10: G44.309

›Painful ophthalmoplegia from granulomatous inflammation

›Steroid-responsive, diagnosis of exclusion

›No fever or systemic infection

05Laboratory Tests/lt44

Essential initial labs

›Blood cultures

›Positive in up to 70% of septic CST cases

›Obtain two sets before first antibiotic dose

›Most common organisms: Staphylococcus aureus (including MRSA), streptococci

›Gram-negative rods and anaerobes also implicated

›Complete blood count with differential

›Leukocytosis expected in septic CST

›WBC > 15 x 10^9/L common

›Neutrophilia with left shift typical

›Thrombocytopenia — may suggest disseminated infection or HIT

›Inflammatory markers

›CRP — elevated; tracks treatment response

›ESR — elevated in CST

›Procalcitonin — may help distinguish septic from aseptic etiology

›Elevated procalcitonin supports bacterial source

Coagulation and metabolic panel

›Coagulation studies

›PT/INR — baseline before anticoagulation initiation

›aPTT — baseline; used to monitor UFH therapy

›Fibrinogen and D-dimer

›D-dimer elevated in CVT but has limited negative predictive value with high clinical suspicion

›Normal D-dimer does NOT exclude CST when pretest probability is high

›Basic metabolic panel

›Renal function — creatinine and electrolytes for contrast imaging and LMWH dosing

›Blood glucose — hyperglycemia associated with worse outcomes and present in diabetic patients

›Liver function tests — baseline before systemic anticoagulation

06Diagnostic Tests/dt65

Scoring Systems

›Clinical diagnosis framework

›No validated scoring system for CST in current use

›Diagnosis is clinical + imaging-confirmed

›High index of suspicion is the cornerstone of timely diagnosis

›Severity stratification

›Mild: unilateral orbital signs, preserved vision, stable mental status

›Moderate: bilateral orbital involvement, diplopia, no vision loss

›Severe: bilateral involvement with vision loss, RAPD, altered mental status, sepsis

›Critical: intracranial complications (meningitis, abscess, venous infarction, stroke)

›RAPD prognostic score

›Presence of RAPD: mortality 37.5% vs 0% in those without

›New RAPD mandates urgent ophthalmology consultation and escalation

CT

›CT head and orbits with IV contrast

›First-line imaging in the ED — widely available, rapid

›Delayed-phase (venous phase) imaging preferred for cavernous sinus evaluation

›Sensitivity approximately 60–80% without contrast; significantly improved with contrast

›Key CT findings for CST

›Filling defect within the cavernous sinus

›Expansion and asymmetry of the cavernous sinus

›Convexity of the lateral wall (normally concave)

›Heterogeneous density within the cavernous sinus

›Dilated superior ophthalmic vein

›Periorbital fat stranding and proptosis

›Additional CT findings

›Sinusitis — opacification of paranasal sinuses

›Orbital abscess or periorbital cellulitis

07Disposition/dispo31

Admission and level of care

›All patients with confirmed or suspected CST require inpatient admission

›ICU-level admission indicated for all cases

›Average length of hospitalization approximately 21 days

›High-acuity condition — observation alone is not appropriate

›ICU triggers

›Altered mental status or declining GCS

›Sepsis or septic shock

›Vision loss or rapidly progressive proptosis

›Bilateral orbital involvement

›Intracranial complications on imaging

›Step-down or intermediate care

›Clinically improving, hemodynamically stable

›Responding to antibiotics and anticoagulation after 48–72 hours

Transfer criteria

›Indications for transfer to higher level facility

›Neurosurgical intervention needed (abscess drainage, endovascular thrombectomy)

›Transfer to facility with neurosurgical and neurointerventional capability

›ENT surgical drainage not available at current facility

›Ophthalmologic surgery not available (orbital decompression)

›Requires MRI not available at current facility

Discharge criteria

›Discharge not appropriate in acute CST

›All patients require prolonged IV antibiotic therapy (minimum 3–4 weeks, often 6 weeks)

›Oral anticoagulation transition possible prior to discharge with reliable follow-up

›Must have improving cranial nerve function and no new deficits

›Stable or improving vision on ophthalmologic assessment

›Afebrile for >48 hours with improving inflammatory markers

08Treatment/t78

Immediate resuscitation

›Sepsis bundle

›IV fluid resuscitation

›30 mL/kg isotonic crystalloid bolus if hypotensive

›Reassess hemodynamics after each 500 mL aliquot

›Vasopressors for refractory hypotension

›Norepinephrine 0.1–0.5 mcg/kg/min IV

›Titrate to MAP >= 65 mmHg

›First-line vasopressor in septic shock

›Oxygen supplementation

›Target SpO2 >= 94%

›Supplemental O2 by nasal cannula or face mask

Antibiotic therapy

›Empiric antibiotic regimen — initiate immediately after blood cultures

›Vancomycin — MRSA coverage

›25–30 mg/kg IV loading dose (based on actual body weight)

›Subsequent dosing 15–20 mg/kg IV every 8–12 hours

›Target trough 15–20 mg/L or AUC/MIC 400–600

›Adjust for renal function

›Ceftriaxone — gram-negative and streptococcal coverage

›2 g IV every 12 hours

›Alternative: cefotaxime 2 g IV every 6–8 hours

›Metronidazole — anaerobic coverage

›500 mg IV every 8 hours

›Alternative to metronidazole: piperacillin-tazobactam 4.5 g IV every 6 hours (covers anaerobes and gram-negatives)

›Duration of IV antibiotics

›Minimum 3–4 weeks; often 6 weeks for complete treatment

›Adjust based on culture and sensitivity results

›Antifungal coverage for mucormycosis/Aspergillus

›Liposomal amphotericin B 5 mg/kg/day IV

›Indicated when black eschar, rapid tissue necrosis, or immunocompromised host

›Surgical debridement essential alongside antifungal therapy

Anticoagulation

›Heparin anticoagulation — initiate when CST confirmed on imaging

›LMWH — preferred first-line agent

›Enoxaparin 1 mg/kg subcutaneous every 12 hours

›Adjust for renal impairment (CrCl < 30 mL/min — consider UFH instead)

›Anti-Xa monitoring target: 0.6–1.0 units/mL (peak, 4 hours post-dose)

›More predictable pharmacokinetics and lower HIT risk than UFH

›Unfractionated heparin (UFH) — alternative when rapid reversal needed

›80 units/kg IV bolus followed by 18 units/kg/hour infusion

›Titrate to aPTT 60–100 seconds (or per institutional protocol)

›Preferred in renal failure or when surgery anticipated

›Evidence for anticoagulation

›Adjusted OR for mortality with anticoagulation: 0.067 (95% CI 0.009–0.475)

›Anticoagulation recommended even in the presence of hemorrhagic venous infarction

›Transition to oral anticoagulation

›Warfarin target INR 2.0–3.0

›3–6 months for transient risk factors

›Longer duration if chronic thrombophilia identified

›DOACs (direct oral anticoagulants) — emerging evidence supports use in CVT

›Dabigatran or rivaroxaban may be considered per AHA 2024 guidelines

›Avoid non-heparin anticoagulants if HIT or VITT suspected

›Test anti-PF4 antibodies

›Alternative agents: argatroban, fondaparinux, bivalirudin

Surgical intervention

›Source control — surgical drainage

›Endoscopic sinus surgery

›Drainage of sphenoid, ethmoid, or other involved sinuses

›Performed in up to 80% of septic CST cases in some series

›Reduces infectious burden and improves antibiotic penetration

›Drainage of associated abscesses

›Orbital abscess drainage when present

›Dental abscess extraction or drainage

›Deep space neck abscess drainage if applicable

›Neurosurgical intervention

›Cerebral abscess drainage for intracranial complications

›Endovascular thrombectomy in refractory cases without improvement on anticoagulation

Adjunctive treatments

›Corticosteroids — controversial, not routinely recommended

›AHA guidelines do not routinely recommend corticosteroids for CST

›May be considered for severe orbital inflammation on a case-by-case basis

›Dexamethasone 4–8 mg IV every 6 hours if used

›Risks: may worsen infection control, immunosuppression

›Anticonvulsants

›Indicated if seizures occur

›Levetiracetam 500–1500 mg IV every 12 hours

›Loading dose 20–60 mg/kg IV for status epilepticus

›Prophylactic anticonvulsants not routinely recommended without seizures

›IOP management

›Topical beta-blocker — timolol 0.5% eye drops twice daily

›Acetazolamide 250 mg orally every 6 hours for elevated ICP

›Lateral canthotomy for orbital compartment syndrome with vision loss

09Special Populations/sp65

Pregnancy

›Epidemiology and risk in pregnancy

›Pregnancy and postpartum state are independent risk factors for CVT

›Hypercoagulable state — elevated clotting factors, decreased protein S

›CST may occur in any trimester or up to 4 weeks postpartum

›Additional risk: severe dehydration from hyperemesis gravidarum

›Imaging considerations

›MRI without gadolinium preferred over CT to avoid fetal radiation

›Gadolinium contrast — classified FDA Category C; avoid unless benefits outweigh risks

›MR venography without contrast (time-of-flight technique) as initial study

›CT acceptable if MRI unavailable and diagnosis cannot be delayed

›Fetal radiation dose from head CT is low (< 1 mGy)

›Treatment modifications in pregnancy

›LMWH — safe in all trimesters; does not cross placenta

›Enoxaparin 1 mg/kg subcutaneous every 12 hours

›Anti-Xa monitoring recommended (target 0.6–1.0 units/mL peak)

›UFH — safe alternative; does not cross placenta; preferred near delivery for reversal with protamine

›Warfarin — contraindicated in first trimester (teratogenic); also avoided near delivery

›DOACs — contraindicated in pregnancy (safety data insufficient)

›Antibiotics — avoid doxycycline and fluoroquinolones; use penicillin/cephalosporins + metronidazole

›Vancomycin — acceptable in pregnancy when MRSA coverage needed

Geriatric

›Age-related considerations

›Atypical presentations more common in elderly

›Insidious onset, less prominent fever

›Altered mental status may be attributed to other causes — maintain high suspicion

›Increased comorbidity burden

›Diabetes mellitus, malignancy, immunosuppression common

›Higher baseline vascular disease increases stroke risk

›Pharmacologic considerations

›LMWH dosing — adjust for renal function (eGFR)

›eGFR < 30 mL/min: use UFH or reduce LMWH dose with anti-Xa monitoring

›Vancomycin — increased nephrotoxicity risk; careful AUC-guided monitoring

›Monitor renal function every 48 hours minimum

›Increased bleeding risk on anticoagulation

›HAS-BLED score consideration for anticoagulation duration decisions

›Polypharmacy — drug interaction review before antibiotic and anticoagulant initiation

›Functional outcomes

›Higher rates of persistent neurological deficits

›Vision loss more prevalent and less likely to fully recover

›Increased mortality compared to younger patients

Pediatrics

›Epidemiology in children

›CST is rare in children; sinusitis remains the most common etiology

›Sphenoid sinusitis in school-age children and adolescents

›Infants — otitis media and mastoiditis more common preceding infections

›AHA/ASA 2019 pediatric CVT guidelines provide management framework

›Clinical features in children

›Headache, fever, and periorbital swelling may mimic orbital cellulitis

›Seizures more common in pediatric CVT than adults

›Bilateral eye involvement should raise CST suspicion even in children

›Antibiotic dosing in pediatrics

›Vancomycin 15 mg/kg IV every 6 hours (maximum 60 mg/kg/day)

›Target trough 10–15 mg/L or AUC-guided dosing per pediatric pharmacist

›Ceftriaxone 50 mg/kg IV every 12 hours (maximum 2 g per dose)

›Metronidazole 10 mg/kg IV every 8 hours (maximum 500 mg per dose)

›Anticoagulation in children

›Unfractionated heparin — 75 units/kg IV bolus, then 20 units/kg/hour

›Titrate to aPTT 60–85 seconds

›LMWH (enoxaparin) — weight-based dosing

›< 2 months: 1.5 mg/kg SC every 12 hours

›> 2 months: 1.0 mg/kg SC every 12 hours

›Anti-Xa target 0.5–1.0 units/mL

›Anticoagulation duration — minimum 3 months for first episode

›AHA/ASA 2019 supports anticoagulation for pediatric CVT (Class IIa)

›Imaging in children

›MRI with MR venography preferred — no ionizing radiation

›CT acceptable in emergency when MRI not rapidly available

10Background/b84

Epidemiology

›Incidence and demographic distribution

›Incidence 0.2–1.6 per 100,000 population

›Rare but life-threatening condition

›No strong sex predilection in septic CST

›Aseptic CST: female predominance due to OCP use

›Mortality and morbidity

›Contemporary mortality approximately 11% with modern management

›Pre-antibiotic era mortality approached 100%

›Morbidity (persistent neurological deficits) in 15–30% of survivors

›Persistent extraocular movement limitation in approximately 30% of survivors

›Persistent vision loss in approximately 17% of survivors

›Etiology distribution

›Septic CST accounts for the majority of cases

›Aseptic causes include thrombophilia, malignancy, dehydration, OCP use, and post-traumatic

›Comorbidities

›Diabetes mellitus present in up to 70% of septic CST cases in some series

›Immunocompromised state increases risk and mortality

Pathophysiology

›Anatomy of the cavernous sinus

›Paired venous structures at the skull base flanking the sella turcica

›Located lateral to the pituitary gland and sphenoid sinus

›Intercavernous sinuses connect the two sides — explains bilateral spread

›Structures traversing the cavernous sinus

›Internal carotid artery (within the sinus)

›Cranial nerve VI (abducens) — within the sinus, most vulnerable to compression

›Cranial nerves III, IV, V1, V2 — in the lateral wall of the sinus

›Venous drainage connections

›Superior ophthalmic vein drains the orbit into the cavernous sinus

›Facial veins (valveless) communicate with angular and ophthalmic veins

›Connects to petrosal sinuses, sigmoid sinuses, and basilar plexus

›Pathogenesis of septic CST

›Infection spreads from face and sinuses via valveless venous connections

›Retrograde thrombophlebitis from facial infections via angular/ophthalmic vein

›Direct extension from sphenoid or ethmoid sinusitis

›Hematogenous seeding (less common)

›Thrombus formation

›Bacterial endotoxins and local inflammation trigger coagulation cascade

›Fibrin thrombus forms within the cavernous sinus

›Obstruction of venous outflow elevates intraorbital pressure

›Consequences of thrombosis

›Elevated intraocular pressure — proptosis, chemosis

›Cranial nerve compression — ophthalmoplegia, sensory deficits

›Retrograde extension — superior ophthalmic vein thrombosis

›Anterograde extension — petrosal sinuses, sigmoid sinus, jugular vein

›Septic emboli — pulmonary septic emboli occur in minority of cases

›Intracranial complications — venous infarction, brain abscess, meningitis

›Pathogenesis of aseptic CST

›Systemic hypercoagulable state drives thrombus formation

›Inherited thrombophilias — factor V Leiden, prothrombin mutation

›Acquired — antiphospholipid syndrome, malignancy, OCP use, pregnancy

›VITT — anti-PF4 antibody-mediated platelet activation with thrombocytopenia

›Inflammatory cascade similar to septic form once thrombosis established

Therapeutic Considerations

›Evidence base for anticoagulation

›Anticoagulation reduces mortality with adjusted OR 0.067 (95% CI 0.009–0.475)

›Systematic review and meta-analysis supports anticoagulation in CST

›Benefit extends to patients with hemorrhagic venous infarction

›AHA 2024 CVT scientific statement

›Anticoagulation recommended for all CVT including CST (Class I recommendation)

›LMWH preferred over UFH for initial therapy in stable patients

›DOACs (dabigatran, rivaroxaban) may be considered for transition after acute phase

›ACCP 2012 Antithrombotic Therapy Guidelines

›Anticoagulation recommended for CVT even in the presence of intracranial hemorrhage

›Antibiotic evidence

›No randomized trials for antibiotic regimens in CST specifically

›Recommendations extrapolated from intracranial infection guidelines and case series

›Vancomycin + third-generation cephalosporin + metronidazole most widely used empiric regimen

›Culture-directed therapy is the goal — positive blood cultures in up to 70% of septic CST

›Duration of 3–6 weeks based on expert consensus and case series data

›Role of corticosteroids

›Not routinely recommended by AHA guidelines

›Concern for immunosuppression and propagation of infection

›May be considered for severe orbital inflammation with vision threat

›Evidence limited to case series and expert opinion

›Surgical considerations

›Endoscopic sinus surgery reduces infectious burden

›Performed in up to 80% of cases in specialized centers

›Especially beneficial for sphenoid and ethmoid sinusitis-related CST

›Endovascular thrombectomy — reserved for refractory cases

›No randomized evidence; limited case series data

›Consider when anticoagulation fails and clinical deterioration occurs

›ICD-10 codes

›G08 — Intracranial and intraspinal phlebitis and thrombophlebitis (includes CST)

›I67.6 — Nonpyogenic thrombosis of intracranial venous system (aseptic CVT)

›J32.9 — Chronic sinusitis (contributing cause code)

›B46.1 — Rhinocerebral mucormycosis (if fungal etiology)

11Patient Discharge Instructions/pdi28

copy discharge instructions

›Cavernous Sinus Thrombosis — Discharge Instructions

›What is cavernous sinus thrombosis?

›A blood clot in a venous space at the base of your skull, usually caused by a spread of infection from sinuses or the face

›It is a serious condition that required hospitalization and will need continued careful follow-up

›Your medications

›Take your antibiotic and blood thinner (anticoagulant) exactly as prescribed

›Do not stop anticoagulation without consulting your doctor

›If on warfarin, keep all INR (blood test) monitoring appointments

›Activity

›Avoid strenuous activity until cleared by your doctor

›Do not drive if you have double vision or reduced vision

›Wound care

›If you had sinus surgery, follow your ENT surgeon's wound care instructions

›Keep dental infection sites clean per your dentist's instructions

›Return to emergency department immediately for

›New or worsening headache

›Worsening eye swelling, redness, or pain

›Double vision that is new or worsening

›Any change in vision, including blurring or vision loss

›Confusion, difficulty speaking, or weakness on one side

›Seizures

›Fever (temperature > 38°C or 100.4°F)

›Signs of bleeding if on anticoagulation — unusual bruising, blood in urine or stool, severe headache

›Follow-up appointments

›Ophthalmology within 1–2 weeks of discharge

›Neurology within 1–2 weeks of discharge

›Infectious disease or treating physician for antibiotic management

12References/r24

Guidelines and key sources

›Long B, Field SM, Singh M, Koyfman A. High Risk and Low Prevalence Diseases: Cavernous Sinus Thrombosis. The American Journal of Emergency Medicine. 2024. PMID: 38959601

›Comprehensive emergency medicine review of CST diagnosis and management

›Housley SB, McPheeters MJ, Raygor KP, et al. Cavernous Sinus Thrombosis. Neurosurgery Clinics of North America. 2024. PMID: 38782523

›Neurosurgical perspective on anatomy, pathogenesis, and intervention

›Halawa O, Gibbons A, Van Brummen A, Li E. Septic Cavernous Sinus Thrombosis: Clinical Characteristics, Management, and Outcomes. Journal of Neuro-Ophthalmology. 2025. PMID: 38654412

›Key findings including RAPD prognostic significance and mortality data

›Saposnik G, Bushnell C, Coutinho JM, et al. Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association. Stroke. 2024

›AHA 2024 CVT guidelines — anticoagulation recommendations including LMWH and DOACs

›Caranfa JT, Yoon MK. Septic Cavernous Sinus Thrombosis: A Review. Survey of Ophthalmology. 2021. PMID: 33831391

›Ophthalmologic findings, IOP data, and surgical management review

›Akarapas C, Wiwatkunupakarn N, Sithirungson S, Chaiyasate S. Anticoagulation for Cavernous Sinus Thrombosis: A Systematic Review and Individual Patient Data Meta-Analysis. European Archives of Oto-Rhino-Laryngology. 2025. PMID: 39312001

›Strongest mortality evidence for anticoagulation (OR 0.067)

›Ropper AH, Klein JP. Cerebral Venous Thrombosis. The New England Journal of Medicine. 2021

›Landmark NEJM review of CVT pathophysiology, diagnosis, and treatment

›Ferriero DM, Fullerton HJ, Bernard TJ, et al. Management of Stroke in Neonates and Children: A Scientific Statement From AHA/ASA. Stroke. 2019

›Pediatric CVT management framework and anticoagulation dosing

›Pannell JS, Corey AS, Shih RY, et al. ACR Appropriateness Criteria Cerebrovascular Diseases. Journal of the American College of Radiology. 2024

›Imaging recommendations including CT venography and MR venography

›Khatri IA, Wasay M. Septic Cerebral Venous Sinus Thrombosis. Journal of the Neurological Sciences. 2016. PMID: 26944152

›Causative organisms, blood culture yield, and antibiotic duration evidence

›Branson SV, McClintic E, Yeatts RP. Septic Cavernous Sinus Thrombosis Associated With Orbital Cellulitis. Ophthalmic Plastic and Reconstructive Surgery. 2018. PMID: 30320718

›Case series on orbital cellulitis-associated CST and surgical outcomes

›Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest. 2012. ACCP 9th Edition Guidelines

›ACCP evidence-based guidelines supporting anticoagulation even with hemorrhagic infarction

Evidence & Review

Evidence & Review